Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029529782> ?p ?o ?g. }
- W2029529782 endingPage "3742" @default.
- W2029529782 startingPage "3735" @default.
- W2029529782 abstract "Abstract Transformation of Philadelphia (Ph)–negative myeloproliferative neoplasms (MPNs) to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is associated with poor response to chemotherapy and short survival. Fifty-four patients with Ph-negative MPN (including 21 essential thrombocythemia [ET], 21 polycythemia vera [PV], 7 primary myelofibrosis, and 5 unclassified MPN) who had progressed to AML (n = 26) or MDS (n = 28) were treated with azacitidine in a patient-named program. Overall response rate was 52% (24% complete response [CR], 11% partial response [PR], 8% marrow CR or CR with incomplete recovery of cytopenias, 9% hematologic improvement) and median response duration was 9 months. Prognostic factors were for overall response the underlying MPN (71% vs 33% responses in ET and PV, respectively; P = .016); prognostic factors for CR achievement were the underlying MPN (14% CR for PV vs 43% for ET; P = .040) and World Health Organization classification at transformation (36% vs 12% CR in MDS and AML, respectively, P = .038). Recurrence of chronic phase features of the initial MPN was observed in 39% of the responders. Median overall survival was 11 months. Azacitidine gives encouraging results in Ph-negative MPN having progressed to AML or MDS, but response duration is short, and consolidation treatments have to be evaluated." @default.
- W2029529782 created "2016-06-24" @default.
- W2029529782 creator A5003273516 @default.
- W2029529782 creator A5004876764 @default.
- W2029529782 creator A5007605254 @default.
- W2029529782 creator A5008609620 @default.
- W2029529782 creator A5011226625 @default.
- W2029529782 creator A5011803879 @default.
- W2029529782 creator A5013766565 @default.
- W2029529782 creator A5014838075 @default.
- W2029529782 creator A5015172846 @default.
- W2029529782 creator A5025925500 @default.
- W2029529782 creator A5027227964 @default.
- W2029529782 creator A5027248801 @default.
- W2029529782 creator A5047145227 @default.
- W2029529782 creator A5053199721 @default.
- W2029529782 creator A5061754443 @default.
- W2029529782 creator A5064103067 @default.
- W2029529782 creator A5067465993 @default.
- W2029529782 creator A5080661528 @default.
- W2029529782 creator A5082438162 @default.
- W2029529782 date "2010-11-11" @default.
- W2029529782 modified "2023-10-10" @default.
- W2029529782 title "Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)" @default.
- W2029529782 cites W1603401075 @default.
- W2029529782 cites W1970161464 @default.
- W2029529782 cites W1974079495 @default.
- W2029529782 cites W1982078599 @default.
- W2029529782 cites W1989167457 @default.
- W2029529782 cites W1993214853 @default.
- W2029529782 cites W2029868343 @default.
- W2029529782 cites W2038488698 @default.
- W2029529782 cites W2045496640 @default.
- W2029529782 cites W2051181798 @default.
- W2029529782 cites W2056116861 @default.
- W2029529782 cites W2059851299 @default.
- W2029529782 cites W2081279521 @default.
- W2029529782 cites W2087623186 @default.
- W2029529782 cites W2088033042 @default.
- W2029529782 cites W2096638244 @default.
- W2029529782 cites W2106584820 @default.
- W2029529782 cites W2106609638 @default.
- W2029529782 cites W2107398329 @default.
- W2029529782 cites W2112316414 @default.
- W2029529782 cites W2118771330 @default.
- W2029529782 cites W2129510594 @default.
- W2029529782 cites W2130041404 @default.
- W2029529782 cites W2150100099 @default.
- W2029529782 cites W2153515209 @default.
- W2029529782 cites W2159507916 @default.
- W2029529782 cites W2317624320 @default.
- W2029529782 cites W2555136389 @default.
- W2029529782 cites W3147148312 @default.
- W2029529782 cites W4253916874 @default.
- W2029529782 cites W4293241248 @default.
- W2029529782 cites W4376595466 @default.
- W2029529782 cites W4384116820 @default.
- W2029529782 doi "https://doi.org/10.1182/blood-2010-03-274811" @default.
- W2029529782 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20664061" @default.
- W2029529782 hasPublicationYear "2010" @default.
- W2029529782 type Work @default.
- W2029529782 sameAs 2029529782 @default.
- W2029529782 citedByCount "143" @default.
- W2029529782 countsByYear W20295297822012 @default.
- W2029529782 countsByYear W20295297822013 @default.
- W2029529782 countsByYear W20295297822014 @default.
- W2029529782 countsByYear W20295297822015 @default.
- W2029529782 countsByYear W20295297822016 @default.
- W2029529782 countsByYear W20295297822017 @default.
- W2029529782 countsByYear W20295297822018 @default.
- W2029529782 countsByYear W20295297822019 @default.
- W2029529782 countsByYear W20295297822020 @default.
- W2029529782 countsByYear W20295297822021 @default.
- W2029529782 countsByYear W20295297822022 @default.
- W2029529782 countsByYear W20295297822023 @default.
- W2029529782 crossrefType "journal-article" @default.
- W2029529782 hasAuthorship W2029529782A5003273516 @default.
- W2029529782 hasAuthorship W2029529782A5004876764 @default.
- W2029529782 hasAuthorship W2029529782A5007605254 @default.
- W2029529782 hasAuthorship W2029529782A5008609620 @default.
- W2029529782 hasAuthorship W2029529782A5011226625 @default.
- W2029529782 hasAuthorship W2029529782A5011803879 @default.
- W2029529782 hasAuthorship W2029529782A5013766565 @default.
- W2029529782 hasAuthorship W2029529782A5014838075 @default.
- W2029529782 hasAuthorship W2029529782A5015172846 @default.
- W2029529782 hasAuthorship W2029529782A5025925500 @default.
- W2029529782 hasAuthorship W2029529782A5027227964 @default.
- W2029529782 hasAuthorship W2029529782A5027248801 @default.
- W2029529782 hasAuthorship W2029529782A5047145227 @default.
- W2029529782 hasAuthorship W2029529782A5053199721 @default.
- W2029529782 hasAuthorship W2029529782A5061754443 @default.
- W2029529782 hasAuthorship W2029529782A5064103067 @default.
- W2029529782 hasAuthorship W2029529782A5067465993 @default.
- W2029529782 hasAuthorship W2029529782A5080661528 @default.
- W2029529782 hasAuthorship W2029529782A5082438162 @default.
- W2029529782 hasBestOaLocation W20295297821 @default.
- W2029529782 hasConcept C104317684 @default.
- W2029529782 hasConcept C126322002 @default.